Fredun Pharmaceuticals Hits New 52-Week High at Rs. 1877.4

Fredun Pharmaceuticals has reached a significant milestone by hitting a new 52-week high of Rs. 1877.4 today, marking a notable achievement in the microcap pharmaceuticals and biotechnology sector. This new high reflects a robust performance, as the stock has outperformed its sector by 5.04% and has shown a consecutive gain over the last two days, rising 10.25% during this period. The stock opened with a gain of 3.47% today and reached an intraday high of Rs. 1877.4, representing a 5% increase. Fredun Pharmaceuticals is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Over the past year, Fredun Pharmaceuticals has delivered impressive returns of 179.71%, significantly outpacing the Sensex, which has grown by only 9.23%. The company's financial health is underscored by a remarkable annual growth rate in net sales of 39.73% and a net profit increase of 127.87%. With these strong performance indicators, Fredun Pharmaceuticals continues to solidify its position in the market.